2024
Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus
Salib A, Sanchez J, Huggins L, Seddio A, Dhodapkar M, Smith-Voudouris J, Norman M, Koumpouras F, Grauer J. Outcomes following total shoulder arthroplasty in patients with systemic lupus erythematosus. Journal Of Shoulder And Elbow Surgery 2024 PMID: 39154846, DOI: 10.1016/j.jse.2024.07.008.Peer-Reviewed Original ResearchSystemic lupus erythematosus patientsSystemic lupus erythematosusTotal shoulder arthroplastyAdverse eventsImplant survivalLupus erythematosusMultivariate analysisShoulder arthroplastyIncreased oddsTotal shoulder arthroplasty patientsNon-SLE patientsMultivariate logistic regressionImmunomodulatory therapyPostoperative complicationsElixhauser Comorbidity IndexAdult patientsNinety-dayUnivariate analysisSurgical planningComorbidity indexPatient counselingGlenohumeral osteoarthritisPatientsComorbid conditionsOrthopedic-relatedA dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNAChimeric antigen receptors: “CARs” in the fast lane for rheumatology
Johnson N, Koumpouras F. Chimeric antigen receptors: “CARs” in the fast lane for rheumatology. Current Opinion In Rheumatology 2024, 36: 176-183. PMID: 38517338, PMCID: PMC11224568, DOI: 10.1097/bor.0000000000001012.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T treatmentCAR-TB cellsAutoimmune diseasesRheumatologic diseasesReview current clinical dataSevere refractory autoimmune diseasesReconstitution of B cellsRefractory autoimmune diseasesTreatment of rheumatologic diseasesB-cell malignanciesCompassionate use programB cell populationsLaboratory remissionRefractory SLECD19-CARField of autoimmunityRefractory diseaseClinical responseNaive phenotypeSevere lupusMultiple myelomaAutoimmune modelsT cells
2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
Merrill J, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh S, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James J, Zack D. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial. Arthritis & Rheumatology 2023, 75: 2185-2194. PMID: 37459248, DOI: 10.1002/art.42652.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLoss of improvementPrimary endpointLupus erythematosusWeek 32B cellsEfficacy-evaluable populationImproved disease activityPhase 2 trialProportion of patientsTreatment-related toxicityTreatment of patientsPlacebo-ControlledCorticosteroid injectionDisease activityInfusion reactionsTrough concentrationsPatient subsetsPlasma cellsPatientsSecondary analysisMonoclonal antibodiesStatistical significanceEndpointPlaceboVascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis
Xu S, Patrignelli R, Ramachandran S, Koumpouras F, Desir D, Ko C, Gehlhausen J. Vascular-Targeted Therapy for Systemic Lupus Erythematosus–Associated Vasculitis. JAMA Dermatology 2023, 159: 460-462. PMID: 36884229, DOI: 10.1001/jamadermatol.2023.0077.Peer-Reviewed Original Research
2021
Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy
Koumpouras F, Bucala R. Chapter 11 Interferons and cytokines in SLE pathogenesis and therapy. 2021, 169-180. DOI: 10.1016/b978-0-12-820583-9.00015-4.Peer-Reviewed Original Research
2020
IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis
Shin MS, Kim D, Yim K, Park HJ, You S, Dong X, Koumpouras F, Shaw AC, Fan R, Krishnaswamy S, Kang I. IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis. Cellular Immunology 2020, 355: 104155. PMID: 32619811, PMCID: PMC7415611, DOI: 10.1016/j.cellimm.2020.104155.Peer-Reviewed Original ResearchConceptsSingle-cell RNA-seqHuman effector memory CD8Effector memory CD8T cellsIL-7RαMemory CD8Gene regulationTranscription factorsRNA-seqPossible biological significanceDownstream eventsEM CD8Expression patternsExpressional relationshipDifferential expressionCytokine receptorsComprehensive landscapeHigh-dimensional cytometryBiological significanceIL-7 receptor alphaKey moleculesIL-7 receptor alpha chainReceptor alpha chainBiological implicationsHeterogeneous cell subsetsStand Together and Deliver: Challenges and Opportunities for Rheumatology Education During the COVID‐19 Pandemic
Koumpouras F, Helfgott S. Stand Together and Deliver: Challenges and Opportunities for Rheumatology Education During the COVID‐19 Pandemic. Arthritis & Rheumatology 2020, 72: 1064-1066. PMID: 32270923, PMCID: PMC7262333, DOI: 10.1002/art.41278.Peer-Reviewed Original ResearchDefining heterogeneity and biological signature in human effector memory CD8+ T cells expressing different levels of IL-7 receptor alpha by high-dimensional analysis
Shin M, Kim D, Park H, Dong X, Koumpouras F, Kang I. Defining heterogeneity and biological signature in human effector memory CD8+ T cells expressing different levels of IL-7 receptor alpha by high-dimensional analysis. The Journal Of Immunology 2020, 204: 154.19-154.19. DOI: 10.4049/jimmunol.204.supp.154.19.Peer-Reviewed Original ResearchHuman effector memory CD8EM CD8Effector memory CD8T cellsIL-7RαMemory CD8Cell subsetsIL-7 receptor alphaIL-7 receptor alpha chainT cell subsetsCo-stimulatory moleculesT cell heterogeneityHigh-dimensional single-cell analysisReceptor alpha chainLupus patientsImmune landscapeCell surface moleculesHeterogeneous cell subsetsT-betCD8Effector functionsDifferential expressionReceptor alphaSingle-cell RNA-seq analysisPathologic conditions
2019
FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Khosroshahi A, Sheikh S, James J, Guthridge J, Rathi G, Burington B, Foster P, Zack D. FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). 2019, 761.2-762. DOI: 10.1136/annrheumdis-2019-eular.4234.Peer-Reviewed Original Research98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Sheikh S, Khosroshahi A, Foster P, Zack D. 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). 2019, a73-a74. DOI: 10.1136/lupus-2019-lsm.98.Peer-Reviewed Original Research
2018
LB1601 Dermatomyositis-related panniculitis of the neck
Valladares H, Ramachandran S, Koumpouras F. LB1601 Dermatomyositis-related panniculitis of the neck. Journal Of Investigative Dermatology 2018, 138: b23. DOI: 10.1016/j.jid.2018.06.141.Peer-Reviewed Original Research
2015
Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double‐Blind, Placebo‐Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology 2015, 67: 1848-1857. PMID: 25777546, PMCID: PMC4732716, DOI: 10.1002/art.39108.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdultAntibodies, Anti-IdiotypicAntigensCarrier ProteinsCholecalciferolCytoskeletal ProteinsDietary SupplementsDNADose-Response Relationship, DrugDouble-Blind MethodFemaleGene Expression RegulationHumansLupus Erythematosus, SystemicMaleMicroarray AnalysisMiddle AgedMyxovirus Resistance ProteinsProspective StudiesRNA-Binding ProteinsVitamin DConceptsPercentage of patientsVitamin D3Vitamin DIFN signatureTreatment groupsSLE patientsInterferon signatureSystemic lupus erythematosus seraDNA antibody levelsVitamin D repletionPlacebo-controlled trialVitamin D deficientVitamin D supplementationVitamin D3 supplementationSubset of patientsSystemic lupus erythematosusD supplementationD deficientD3 supplementationDisease activityImmunologic outcomesInactive diseaseAdverse eventsBaseline characteristicsLupus erythematosus
2014
Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
ACCESS Trial Group, Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis & Rheumatology. 2014 Nov;66(11):3096-104Peer-Reviewed Original Research
2011
133 Hydroxychloroquine-Induced Lipidosis: Boon for Lupus Nephritis Becomes Bane
Jindal N, Koumpouras F, McHale T, Bastacky S, Liang K. 133 Hydroxychloroquine-Induced Lipidosis: Boon for Lupus Nephritis Becomes Bane. American Journal Of Kidney Diseases 2011, 57: b50. DOI: 10.1053/j.ajkd.2011.02.136.Peer-Reviewed Original Research
2010
Chapter 85 Sjögren Syndrome
Koumpouras F. Chapter 85 Sjögren Syndrome. 2010, 855-857. DOI: 10.1016/b978-1-4160-6109-0.00085-x.Peer-Reviewed Original ResearchChapter 90 Rheumatic Manifestations of Systemic Disorders
Koumpouras F. Chapter 90 Rheumatic Manifestations of Systemic Disorders. 2010, 878-882. DOI: 10.1016/b978-1-4160-6109-0.00090-3.Peer-Reviewed Original ResearchLead Authors and Contributors
Benjamin I, Tariq S, Beland S, Benjamin I, Bull D, Hamdan M, Li D, Litwin S, Michaels A, Morshedzadeh J, Stehlik J, Whitehead K, Victor R, Vongpatanasin W, Rounds S, Aliotta J, Casserly B, Jankowich M, McCool F, Eagle K, Lau W, Harris R, Andreoli T, Basford A, Cavanaugh K, Dwyer J, Golper T, Krause M, Ikizler T, Lewis J, Luther J, Pirkle J, Portilla D, Safirstein R, Schulman G, Shah S, Zent R, Wolfe M, Blanton W, Bliss C, Farraye F, Huang C, Jacobson B, Lichtenstein D, Lowe R, Mishkin D, Moore T, Oviedo J, Pedrosa M, Schimmel E, Schroy P, Singh S, Tseng C, Fallon M, Arguedas M, Garcia-Gallont R, Kochar R, McGuire B, Mönkemüller K, Neumann H, Sheikh A, Varadarajulu S, Berliner N, Lacy J, Rinder C, Rinder H, Rose M, Seropian S, Tormey C, Torres R, Wang E, Griggs J, Burtness B, Khorana A, Lantz P, Todd R, Smith R, Brooks D, Gopalakrishnan G, Hamdy O, Warren M, Ziegler T, Braunstein G, Barnett P, Herman-Bonert V, Friedman T, Charney P, Carney P, Ehrenthal D, Kottenhahn R, Smith J, Milam D, Starkman J, Stewart A, Greenspan S, Hodak S, Horwitz M, LeBeau S, Roodman G, Moreland L, Agarwal S, Ascherman D, Domsic R, Elliott J, Kao A, Koumpouras F, Kwoh C, Lienesch D, McKinnon-Maksimowicz K, Medsger T, Mohan N, Wing E, Armitage K, Beckwith C, Bobak D, Fairley J, Fulton S, Hileman C, Lange C, Lederman M, Lemonovich T, Lisagaris M, Ray A, Rodriguez B, Salata R, Watkins R, Bradsher R, Griggs R, Berg M, Ciafaloni E, Counihan T, Cheshire W, de los Reyes E, Griggs J, Jackson C, Kerber K, Liu L, Ling G, Lyness J, Lynn D, Marshall F, McCarthy A, Murphy S, Nath A, Roach E, Rogers L, Simon R, Cohen H, Heflin M, Quill T, Holloway R, Hillis L, Lange R. Lead Authors and Contributors. 2010, ix-xix. DOI: 10.1016/b978-1-4160-6109-0.00138-6.Peer-Reviewed Original Research
2008
Rheumatic Manifestations of Systemic Disorders
Andreoli and Carpenter’s Cecil Essentials of Medicine, 8th Ed. 2008, pgs. 878-882Peer-Reviewed Original ResearchSjögren’s Syndrome
Andreoli and Carpenter’s Cecil Essentials of Medicine, 8th Ed. 2008, pgs. 855-857Peer-Reviewed Original Research